We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · January 04, 2022

ASH 2021: Addition of Ivosidenib to Azacitidine Improved Outcomes in Select Patients With Untreated Acute Myeloid Leukemia

Health-related quality of life assessment also favored addition of ivosidenib

PracticeUpdate Editorial Team


Further Reading